AI in Oncology Market to Reach $9.1 Billion by 2035 | Roche Diagnostics, IBM Watson Health, GE Healthcare Among Key Players

The global AI in oncology market, valued at USD 1.7 billion in 2024, is on track to reach USD 2.4 billion in 2025 and USD 9.1 billion by 2035, advancing at a CAGR of 14.1% over the forecast period. With more than 35 million new cancer cases projected worldwide by 2050 and cancer-related deaths expected to climb 72% by 2030, the business case for AI-powered oncology tools has never been more concrete.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/ai-in-oncology-market/request-sample.html

Understanding the AI in Oncology Opportunity
Cancer remains the leading cause of death globally, and the gap between diagnostic demand and available clinical capacity keeps widening. Artificial intelligence addresses that gap directly, enabling clinicians to detect malignancies earlier, personalize treatment regimens, and process imaging data at a scale no human team can match. The early detection of precancerous lesions, where timely intervention materially reduces the risk of malignant progression, stands as one of the most clinically and commercially validated use cases in this domain.

The economics are equally compelling. AI-powered tools significantly reduce the cost of cancer testing and treatment, giving healthcare systems under budget pressure a practical path to improving outcomes without proportional spending increases. Global spending on artificial intelligence surpassed USD 110 billion in 2024, and oncology continues to attract a disproportionate share of that capital. Recent deal activity reinforces the momentum: in January 2026, AstraZeneca acquired Modella AI to integrate generative AI agents into oncology R&D, while GSK committed USD 50 million upfront in a deal with Noetik to analyze spatial omics data for novel cancer target identification. That same month, Insilico Medicine and Servier announced an USD 888 million partnership built around Insilico's Pharma.AI platform for small molecule drug discovery in oncology.

Clinicians working inside the market echo the data. Douglas Flora, President of the Association of Cancer Care Centers, has identified pattern recognition and workflow automation as the near-term high-value applications of AI in oncology, with decision-support capabilities expected to expand further in subsequent years.

Key Growth Drivers
Rising global cancer burden creating demand for scalable diagnostics. Cancer incidence is accelerating across every major region, driven by aging populations and lifestyle risk factors. With over 35 million new cases projected by 2050, health systems need diagnostic tools that scale without proportional increases in specialist headcount. AI solutions fill that requirement directly.
AI integration into pharmaceutical drug discovery. The convergence of AI and molecular biology is shortening drug discovery timelines and improving the probability of clinical success. Companies are investing heavily in AI platforms that identify novel cancer targets and simulate trial outcomes, compressing development cycles that previously took a decade. The Insilico-Servier and GSK-Noetik deals are recent, high-value examples of this shift.

Personalized medicine and biomarker-driven treatment. AI tools that analyze patient genomic profiles, tumor characteristics, and treatment histories are enabling oncologists to move from population-level protocols to individualized therapy plans. This is both a clinical priority and a commercial driver, as payers and healthcare systems increasingly require demonstrated efficacy at the individual patient level.

Government-backed AI adoption programs. Public sector investment is accelerating market entry at scale. India's AI Mission and National Cancer Grid awarded grants worth up to INR 50 lakh each to 10 AI cancer detection projects in March 2026, with deployment planned across public health systems. Initiatives of this kind create institutional demand that bypasses the typical enterprise sales cycle.

Venture capital confidence sustaining early-stage innovation. Investment in the AI in oncology domain is concentrated in venture capital rounds, which account for 70% of all funding activity. Freenome has raised USD 300 million and Lunit USD 61 million in notable rounds, with Casdin Capital, Baillie Gifford, and Google Ventures among the most active participants. This sustained capital inflow is expanding the number of commercially viable tools entering hospital and clinical workflows.

Market Segmentation
The AI in oncology market breaks down across three primary dimensions: type of cancer, type of end user, and geography. By cancer type, the solid malignancies segment holds the largest share of the market in 2025, a position it will maintain through 2035. The scale and diversity of solid tumor presentations, combined with the urgent need for precise, scalable diagnostic tools in this category, account for its leading position. Other tracked segments include breast cancer, lung cancer, prostate cancer, colorectal cancer, and brain tumors. By end user, hospitals are the primary customer, with 52% of market participants offering AI oncology solutions directly to hospital systems, followed by research institutes at 17%.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/ai-in-oncology-market/request-quote.html

Regional Insights
Europe leads the global AI in oncology market, capturing approximately 33% of market share in 2025, a position it will hold through 2035 with more than 30% revenue share. The region's combination of aging demographics, high cancer prevalence, rising healthcare costs, and strong institutional interest in precision medicine has made it the most active geography for AI adoption in oncology. Within Europe, the UK accounts for a significant concentration of market participants.

Asia-Pacific is the fastest-growing region, with a projected CAGR of 14.7% through 2035, outpacing the global average. Rapidly rising cancer incidence across the region, combined with government-backed digital health programs and growing demand for advanced diagnostics, is pulling AI oncology platforms into markets that previously lacked access to specialist care. North America rounds out the competitive geography, with 41% of global AI in oncology companies based in the region, making it the densest hub of commercial activity even as Europe and Asia-Pacific narrow the gap.

Competitive Landscape
The AI in oncology market features more than 75 active companies offering software solutions, with 39% of current players having established operations between 2011 and 2015. Key companies profiled in the Roots Analysis report include Roche Diagnostics, IBM Watson Health, GE Healthcare, CancerCenter.AI, ConcertAI, PathAI, Berg (part of BPGbio), Median Technologies, iCAD, and JLK Inspection, among others. The market is fragmented, with North America hosting the largest concentration of players, but no single incumbent controlling a dominant share. Technology integration agreements account for 30% of all partnership activity, reflecting a competitive environment where companies are building through collaboration as much as through direct competition. Startups are active participants, with venture-backed challengers competing alongside established diagnostics and health IT companies on the basis of AI model performance and clinical validation.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/ai-in-oncology-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.